Table 3. Oligonucleotide toolkits. Through a host of partnerships, many pharmas now have the ability to target multiple types of RNAs using multiple modalities.

Company

Antisense

Small interfering
RNA

MicroRNA (anti-miRNAs
and miRNA mimics)

Other

AstraZeneca plc (LSEA:ZN; NYSE:AZN)

X

 

X

XA

Bristol-Myers Squibb Co. (NYSE:BMY)

X

 

X

 

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

X

X

X

 

Novartis AG (NYSE:NVS; SIX:NOVN)

X

X

 

 

Pfizer Inc. (NYSE:PFE)

X

X

 

 

Sanofi (Euronext:SAN; NYSE:SNY)

X

X

X

 

AModerna Therapeutics Inc.'s messenger RNA therapeutics.